Kornimate/medical-research-clean huggingface dataset:
antibody response to human papillomavirus recombinant vaccine (gardasil®) in girls and young women with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: people with chronic kidney disease are known to have immune response abnormalities, including a diminished response to some vaccinations. those with chronic kidney disease have a disproportionate burden of hpv 6-, 11-, 16- and/or 18-related genital tract disease. due to immune response abnormalities, the ckd population may or may not respond to the recommended three-dose regimen of gardasil®, a vaccine intended to protect against hpv 6-, 11-, 16-, and 18-related genital tract disease. the objective of this study is to measure the antibody response to gardasil® in female patients 9-21 years of age with chronic kidney disease (ckd) (stage 1-4), end-stage kidney disease (stage 5 ckd), and status-post kidney transplant. gardasil® vaccine will be administered according to the fda-approved schedule. blood samples to measure antibody levels to vaccine strains of human papillomavirus (hpv) will be obtained at months 0, 7 and 24.


Eligibility criteria:
inclusion criteria: females, aged 9-21 years, in the following groups: * ckd (defined as estimated glomerular filtration rate between 90 ml/min/1.73m2 and 15 ml/min/1.73m2, as calculated by the schwartz formula) * esrd (egfr \< 15 ml/min/1.73m2, or receiving chronic dialysis \[peritoneal or hemodialysis\]) * status-post kidney transplant exclusion criteria: * within first 3 months post kidney transplant * within 3 months of kidney rejection episode * hypersensitivity to active substances or excipients of gardasil vaccine

Keywords: chronic kidney disease children dialysis kidney transplant human papilloma virus gardasil chronic kidney disease (non-dialysis, dialysis, and kidney transplant) secondary to any cause.
validation of a prognostic score for good visual recovery at one year following combined surgery for cataract and idiopathic epiretinal membrane

Conditions: Surgery for Cataract; Surgery for and Idiopathic Epiretinal Membrane

Summary: the prevalence of idiopathic epiretinal membranes (erm) in people over 50 is estimated at 6 to 19%. even though most cases show very few symptomats, they may induce alterations of the underlying retina and lead to visual impairment likely to greatly diminish quality of life in patients. thanks to the ever-improving quality of vitreo-retinal surgery, ablation of these membranes is a frequent and safe procedure allowing a functional gain in the majority of cases. given the increasing prevalence in the population concerned and the accelerated ageing of the lens after vitrectomy, cataract surgery is often associated with removal of the membrane. on the basis of a study in 142 patients, it was possible to identify clinical and morphological prognostic factors and to inclure them in a score to assess the chances of complete functional recovery at one year following the procedure . age of the patient, the duration of symptoms, initial visual acuity and the quality of the junction between external and internal segments of photoreceptors in optic coherence tomography (oct) appeared as significantly related to visual results. using this score in a new prospective cohort would allow the investigators to make it a reliable and easy-to-use tool at the service of ophthalmologist surgeons and their patients and would provide scientific confirmation of the interest of earlier surgery in this disease. it would also allow the investigators to define in a validated and reproducible manner, a threshold for an ndication for erm surgery, which is currently based on relatively subjective criteria mostly related to visual acuity.


Eligibility criteria:
inclusion criteria: * patients presenting idiopathic erm visible on sd-oct; * indication for combined cataract and erm surgery in a context of a fall in visual acuity or disabling metamorphopsia; * patients who have provided verbal consent; * age ≥ 40 years. exclusion criteria: * patients with secondary erm (diabetes with a history of diabetic retinopathy or maculopathy, occlusion of the retinal veins, uveitis intermediate/posterior uveitis or retinal tear/detachment in the studied eye; * patient présentant toute autre maculopathie ou neuropathie optique ; * patient presenting severe myopia (spherical equivalent ≥ 6 diopters or axial length ≥ 26 mm) ; * patients presenting any other ophthalmological disease independent of the erm and likely to limit visual acuity * patients who have already undergone vitrectomy in the studied eye; * non-visible or poorly visible fundus due to a cloudy vitreous (signal on oct cirrus \<5, quality score on oct spectralis \< 20, signal trend index on oct optovue \< 30) * patients without national health insurance cover * pregnant or breast-feeding women.
intracranial arterial stenosis in young patients

Conditions: Intracranial Arterial Stenosis

Summary: the goal of this study is to evaluate the characteristic of intracranial arterial stenosis among young patients.


Eligibility criteria:
inclusion criteria: * age \< 45 years. * stenosis of a major intracranial artery. exclusion criteria: -
carboplatin with or without thalidomide in treating patients with ovarian epithelial cancer

Conditions: Ovarian Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. thalidomide may stop the growth of ovarian cancer by stopping blood flow to the tumor. purpose: this randomized phase ii trial is studying how well giving carboplatin together with thalidomide works compared to carboplatin alone in treating patients with ovarian epithelial cancer.

objectives: * determine the safety of carboplatin and thalidomide in patients with stage ic-iv ovarian cancer. * determine the antiangiogenic effect of thalidomide in this patient population. * compare the efficacy of carboplatin with or without thalidomide in this patient population. outline: this is a randomized study. patients are randomized to one of two treatment arms. * arm i: patients receive carboplatin iv over 1 hour. treatment continues every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. * arm ii: patients receive carboplatin as in arm i. patients receive thalidomide orally once daily. thalidomide treatment continues for up to 24 weeks commencing on the first day of carboplatin therapy and ceasing 4 weeks after the last course of carboplatin. projected accrual: approximately 30 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed stage ic-iv ovarian epithelial cancer * post-menopausal or * prior bilateral salpingo-oophorectomy and/or total abdominal hysterectomy patient characteristics: age: * over 18 performance status: * who 0-2 life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no other concurrent invasive malignancies * not pregnant * no diabetes mellitus * no chronic neurological disease causing peripheral neuropathy prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no other concurrent cytotoxic agents endocrine therapy: * not specified radiotherapy: * concurrent local radiotherapy for treatment of secondary disease sites allowed surgery: * see disease characteristics

Keywords: stage iv ovarian epithelial cancer stage ic ovarian epithelial cancer stage iia ovarian epithelial cancer stage iib ovarian epithelial cancer stage iic ovarian epithelial cancer stage iiia ovarian epithelial cancer stage iiib ovarian epithelial cancer stage iiic ovarian epithelial cancer
effect of fentanyl on main opioid receptor (oprm1) on human granulosa cells.

Conditions: Stress Reaction; Opioid Use

Summary: opioids is known that produce not only analgesia but also hyperalgesia through activation of central glutaminergic system-gaba. at the same time, recently it was found that the main opioid receptor (oprm1) is present on human granulosa cells and exogenous opiates and their antagonists can influence granulosa cell vascular endothelial growth factor (vegf) production via oprm1, causing ovarian hyperstimulation syndrome. this study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during oocyte retrieval.

the main opioid receptor (oprm1) is present on human granulosa cells and exogenous opiates and their antagonists can influence granulosa cell vascular endothelial growth factor (vegf) production via oprm1, causing ovarian hyperstimulation syndrome. this study aims to investigate if a single exposure to opioids is enough to produce activation of stress mechanism during ultrasound-guided oocyte retrieval. it will be measured the level of cortisone before and 15min after iv administration of fentanyl on blood and on oocyte fluid.

Eligibility criteria:
inclusion criteria: * american physical status i-iii, bmi\<30, exclusion criteria: * heart failure * hepatic failure, hepatitis, * drug abuse * receiving b blockers * receiving b agonists (even bronchodilators)
safety and immunogenicity of recombinant zoster vaccine for kidney transplant recipients

Conditions: Immunosuppression; Vaccine Response Impaired

Summary: the goal of this clinical trial is to compare responses to varicella zoster vaccination between kidney transplant patients on different medication regimens, and their healthy co-habitants. the main questions it aims to answer are: 1. are there differences in vaccination immunological responses in kidney transplant patients on different immunosuppression regimens? 2. are there differences in vaccination immunological responses between kidney transplant patients and their healthy co-habitants? participants will all receive a 2-dose course of shingrix recombinant zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.


Eligibility criteria:
inclusion criteria: * single organ kidney transplant recipient, currently receiving a specific immunosuppression regimen: 1. calcineurin inhibitor (tacrolimus or cyclosporine), antimetabolite (mycophenolate derivative or azathioprine), and oral steroid (n = 30) 2. calcineurin inhibitor (tacrolimus or cyclosporine), mtor inhibitor (sirolimus or everolimus), and oral steroid (n = 30) 3. mtor inhibitor (sirolimus or everolimus), antimetabolite (mycophenolate derivative or azathioprine), and oral steroid (n = 30) * aged \>18 years * estimated glomerular filtration rate (gfr) \> 15 ml/min/1.73m2 * previous documented infection with varicella zoster (known infection history or positive varicella zoster igg result) or * healthy household cohabitant of kidney transplant recipient enrolled in trial (n = 30) * aged \> 50 years * previous documented infection with varicella zoster (known infection history or positive varicella zoster igg result) exclusion criteria: * unable or unwilling to provide informed consent to participate in the trial * no previous infection with varicella zoster (chickenpox) * known allergy to or intolerance of the contents of the shingrix vaccine * current pregnancy * for healthy household cohabitants, history of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy
comparison of thoracic manipulation and muscle energy technique in non-specific mechanical neck pain

Conditions: Neck Pain

Summary: to compare the effects of thoracic manipulation and met in relieving pain.in improving range of motion and in improving functional disability.

neck pain is a common musculoskeletal disorder. mechanical neck pain is also known as non-specific neck pain and is defined as the pain anywhere within the region bounded superiorly by superior nuchal line, inferiorly by an imaginary line through the tip of first thoracic spinous process and laterally by sagittal plane tangential to the lateral borders of the neck in which pain is provoked by sustained neck posture, neck movement, pain on palpation of cervical musculature without pathologies. in most patients, neck pain can be a common cause of disability: it is associated with daily activity limitations, reduction of work productivity and decrease in quality of life. mechanical neck pain is commonly seen in people involved in occupation like computer processing, clerical job, students and people with sedentary life style awkward occupational posture, heavy lifting and physically demanding work. thoracic spine manipulation (tsm) is defined as a high-velocity/low amplitude movement or "thrust" directed at any segment of the thoracic spine. muscle energy technique (met) is a method of treatment that involves the voluntary contraction of subject's muscles in a precisely controlled direction, against a counterforce and producing post isometric relaxation through the influence of the golgi tendon. met is used to decrease pain, stretch tight structures muscle and fascia, reduce muscle tone, improve local circulation, and mobilize joint restriction

Eligibility criteria:
inclusion criteria: * patients who present with a primary complaint of mechanical neck pain (defined as pain in the region between the superior nuchal line and first thoracic spinous process) with limited range of motion. * patients with non-radiating neck pain of moderate intensity scoring 4-8 on the numeric pain rating scale (nprs). * subacute or chronic cases (4 -12 weeks) * have a neck disability index (ndi) score of 20% or greater (10 points or greater on a 0-to-50 scale) * dull aching neck pain increased by sustained postures, neck movement exclusion criteria: * patients with a positive history of trauma, fracture or surgery of the cervical spine. * neck pain with radiation to the arm and upper extremity * diagnosed cases of torticollis, and scoliosis * history of osteoporosis, any heart disease * taken previous physiotherapy session.

Keywords: pain thoracic manipulation muscle energy technique disability range of motion
adequacy of one point fixation of displaced zygomatic complex fracture

Conditions: Zygomatic Fractures

Summary: patients with unilateral non-comminuted zygomatic complex fracture undergo fixation of the complex by a customized plate at one point after 3d virtual simulation and reduction of the complex using mimics software.

history data will be gathered including personal data, medical and surgical history, and family history. clinical examination and photographic records will be carried out to evaluate the magnitude and direction of the displaced zygoma, degree of facial asymmetry, neurosensory affection and functional disturbances. computed tomography (ct) scan: patients will receive a preoperative computed tomography (ct) scan of the facial bones \[ axial cuts, dicom file, gantry tilt zero and minimal thickness of 1 mm\]. the radiographic data will be imported into a surgical simulation software to virtually reduce the fractured zygoma and custom design the plate for fixation. general operative procedures: * all cases will undergo surgery under general anesthesia with nasotracheal intubation. * intraoral maxillary vestibular approach will be used to gain access to the fractured zygomatic complex. reduction of the fractured segment would be achieved using the appropriate techniques and instrumentation. one point orif would be accomplished using the customized plate.

Eligibility criteria:
inclusion criteria: * patients' age range from 15-65 years. * patients with unilateral zygomatic complex fracture * displaced fracture * dentulous or edentulous patients. * patients should be free from any systemic disease that may affect normal healing of bone and predictable outcome. exclusion criteria. patients with systemic diseases as history of radiation therapy or chemotherapy, hematological disorders, neuromotor disorders and autoimmune diseases (may affect normal healing). * patients with comminuted fractures . * delayed presentation 3 weeks or more after the date of trauma.
alveolar-capillary reserve after exercise in chronic obstructive pulmonary disease (copd) (cop-dtpa)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: it is unknown whether individuals with copd exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. the aim of this study is to investigate whether individuals with copd exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass.

it is unknown whether individuals with copd exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. the aim of this study is to investigate whether individuals with copd exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass. the study participants include a control group and a group with copd (gold i-iii). participants are undergoing three study days: (1) measurement of maximal aerobic capacity and lung function test, (2) lung tissue mass and alveolar-capillary permeability is measured at rest and again 2 hours later, immediately after the participant has exercised on a bicycle ergometer and (3) supine cardiac output and pulmonary capillary blood volume will be measured at rest and immediately after exercise.

Eligibility criteria:
inclusion criteria - individuals with copd * men and women * 45-80 years old * copd (gold stage i to iii) * resting arterial oxygenation \> 90% inclusion criteria - healthy controls * men and women * 45-80 years old * non-smokers * normal lung function * same sex, age (± 3 years) as the copd group exclusion criteria - individuals with copd * symptoms of ischemic heart disease * known heart failure * symptoms of illness, including fever, within 2 weeks prior to the study * pregnancy * • known renal or liver diseaseactive smoking (within 3 weeks) exclusion criteria - healthy controls * known chronic lung disease * symptoms of ischemic heart disease * known heart failure * symptoms of illness, including fever, within 2 weeks prior to the study * pregnancy * known renal or liver disease * active smoking (within 3 weeks)

Keywords: copd alveolar-capillary membrane integrity lung tissue mass cardiac output dlco/dlno
duloxetine for lbp

Conditions: Back Pain, Low

Summary: this research study will help determine whether a medication called duloxetine can improve back pain. it is well documented that many participants who come to the er with acute low back pain still have low back pain 3 months later. the investigator team will attempt to determine whether duloxetine can help prevent this.

participants will be eligible to take duloxetine/placebo if insufficient relief of pain after using naproxen for 48 hours has been reported.

Eligibility criteria:
inclusion criteria: * present to emergency department (ed) primary for management of lbp, defined as pain originating between the lower border of the scapulae and the upper gluteal folds. flank pain, that is pain originating from tissues lateral to the paraspinal muscles, will not be included. * musculoskeletal etiology of low back. patients with non-musculoskeletal etiologies such as urinary tract infection, ovarian cysts, or influenza like illness will be excluded. the primary clinical diagnosis, at the conclusion of the ed visit, must be a diagnosis consistent with non-traumatic, non-radicular, musculoskeletal lbp. * patient is to be discharged home. patients admitted to the hospital are more likely to be treated with parenteral medication and therefore are not appropriate for this study. * age 18-64 enrollment will be limited to adults younger than 65 years because of the increased risk of adverse medication effects in older patients. * non-radicular pain. patients will be excluded if the pain radiates below the gluteal folds in a radicular pattern. * pain duration \<2 weeks (336 hours). * prior to the acute attack of lbp, back pain cannot occur more frequently than once per week. * functionally impairing back pain: a baseline score of \> 5 on the roland-morris disability questionnaire exclusion criteria: * not available for follow-up * pregnant or breast-feeding * chronic pain syndrome defined as moderate or severe pain anywhere in their body on \>= 50% of days for at least three months * allergic to or intolerant of investigational medications * contra-indications to non-steroidal anti-inflammatory drugs: 1. history of hypersensitivity to nsaids or aspirin 2. active or history of peptic ulcer disease, chronic dyspepsia, or active or history of gastrointestinal bleed 3. severe heart failure (nyha 2 or worse) 4. uncontrolled blood pressure (\>160/100) 5. glomerular filtration rate (gfr) \<60ml/min 6. current use of anti-coagulants 7. cirrhosis or acute hepatitis * contra-indication to duloxetine: 1. alcohol use disorder 2. chronic liver disease 3. chronic kidney disease 4. glaucoma 5. active use of medication for depression 6. score \> 10 on the patient health questionnaire (phq-9) screening instrument or thoughts of suicide, symptoms of feeling down, depressed, or hopeless phq9 score \>4. now we would like to exclude patients with a phq9 score \>10 or symptoms of feeling down, depressed, or hopeless